id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-E-1179-0008,FDA,FDA-2015-E-1179,CERTIFICATE EXTENDING PATENT TERM to Quarles & Brady LLP,Other,Certifications,2020-08-20T04:00:00Z,2020,8,2020-08-20T04:00:00Z,,2020-08-20T16:50:17Z,,0,0,0900006484815211
FDA-2015-E-1179-0007,FDA,FDA-2015-E-1179,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-05-23T04:00:00Z,2019,5,2019-05-23T04:00:00Z,,2019-05-23T19:51:37Z,,0,0,0900006483cc2940
FDA-2015-E-1179-0006,FDA,FDA-2015-E-1179,"Determination of Regulatory Review Period for Purposes of Patent
Extension; AVEED",Notice,Determinations,2018-02-15T05:00:00Z,2018,2,2018-02-15T05:00:00Z,2018-04-17T03:59:59Z,2018-02-15T16:32:27Z,2018-03136,0,0,0900006482f34648
FDA-2015-E-1179-0005,FDA,FDA-2015-E-1179,Letter from CDER to U.S. Patent and Trademark Office,Other,Letter(s),2017-05-12T04:00:00Z,2017,5,2017-05-12T04:00:00Z,,2017-05-12T18:06:46Z,,0,0,09000064825adc59
FDA-2015-E-1179-0004,FDA,FDA-2015-E-1179,Letter from U.S. Patent and Trademark Office to FDA,Other,Letter(s),2016-12-23T05:00:00Z,2016,12,2016-12-23T05:00:00Z,,2016-12-23T15:58:24Z,,0,0,0900006482433cb3
FDA-2015-E-1179-0003,FDA,FDA-2015-E-1179,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-11-03T05:00:00Z,2015,11,2015-11-03T05:00:00Z,,2015-11-03T15:04:35Z,,0,0,0900006481d0793a
FDA-2015-E-1179-0002,FDA,FDA-2015-E-1179,Patent Extension Application from Buchanan Ingersoll & Rooney (on behalf of Bayer Intellectual Property GmbH),Other,Application,2015-04-09T04:00:00Z,2015,4,2015-04-09T04:00:00Z,,2015-04-09T21:23:46Z,,0,0,0900006481a9c654
FDA-2015-E-1179-0001,FDA,FDA-2015-E-1179,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2015-04-09T04:00:00Z,2015,4,2015-04-09T04:00:00Z,,2015-04-09T21:22:57Z,,0,0,0900006481a9c655